The US Food and Drug Administration (FDA) today announced the approval of Trumenba, the first vaccine licensed in the US to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.
Vaccines do not contribute to multiple sclerosis or other central nervous system demyelinating syndrome onset, according to a study published in JAMA Neurology.
The provision of comprehensive immunization programs for the US population is fraught with difficulties, particularly for the independent primary care/community physician.
Paul Offit, MD, from The Children's Hospital of Philadelphia, talked about vaccine safety and the ongoing public health effects of misinformation about this topic.
Tina Tan, MD, offers insights on preparations for the approaching cold and flu season, which could be one of the worst in years.
Stephen Gluckman, MD, talks about the challenges facing doctors who treat patients infected with Ebola or Enterovirus D68. He also discusses issues facing clinicians as cold and flu season gets underway.